- Hoffmann-La Roche and Gilead Sciences have begun human trials with theneuraminidase inhibitor GS 4104, an oral drug for the prevention and treatment of viral influenza. The dose-ranging trial in healthy volunteers will determine the safety, tolerability and absorption of the drug after administration of a single dose. Following completion of initial trials, the companies plan to commence worldwide studies in patients with both the A and B strains of the influenza virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze